Replies to post #73666 on PharmaCyte Biotech Inc (PMCB)

[1234jklm]

Yes. Janssen recognize that biologics are the future

And their delivery is crucial which is why ciab is so unique and valuable.

Whether your goal is to develop a pipeline through commercial launch, or partner as early as possible, submitting an IND is a critical early milestone for every biotech company. With big Pharma and VC firms competing for the most promising compounds, startups are expected to demonstrate a solid plan for achieving IND acceptance.

Great quote from Jlabs and janssen.

Shows our CEO and team know exactly what they're doing.

Partnership will be announced after our pivotal ind is FDA accepted.

Brilliant execution by CEO Waggoner and his team and also Austrianova.